Pedro Enrique Dorlhiac-Llacer
Overview
Explore the profile of Pedro Enrique Dorlhiac-Llacer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinheiro Junior E, Pracchia L, Beitler de Maurino B, Martinez G, Dorlhiac-Llacer P, Medina A, et al.
Clin Lymphoma Myeloma Leuk
. 2014 Aug;
15(1):e7-e14.
PMID: 25130688
Background: We evaluated the clinical, laboratory, and prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia (ALL). Materials And Methods: In this observational, retrospective, cross-sectional study, we examined...
2.
Bendit I, Sanabani S, Conchon M, Serpa M, Novaes M, Nardinelli L, et al.
Acta Haematol
. 2012 Aug;
128(4):223-32.
PMID: 22922489
Here we compare the management and survival outcomes of chronic myeloid leukemia (CML) patients who had early or late imatinib mesylate (IM) therapy. The cytogenetic and molecular responses of 189...
3.
Serpa M, Sanabani S, Dorlhiac-Llacer P, Nardinelli L, Ferreira P, Martins T, et al.
Acta Haematol
. 2011 Nov;
127(1):56-9.
PMID: 22094354
Despite the beneficial effects of imatinib mesylate, some patients may either not respond or respond suboptimally. Here, we report two chronic myelogenous leukemia patients; one had a suboptimal response according...
4.
Nicolini F, Masszi T, Shen Z, Gallagher N, Jootar S, Powell B, et al.
Leuk Lymphoma
. 2011 Oct;
53(5):907-14.
PMID: 22023530
Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over...
5.
Kleine Neto W, Serpa M, Sanabani S, Bueno P, Velloso E, Dorlhiac-Llacer P, et al.
Clin Med Insights Oncol
. 2011 Jan;
4:163-70.
PMID: 21234297
Here we describe a female patient who developed acute promyelocytic leukemia (APL) characterized by t(l5;17) translocation at diagnosis. The patient began treatment with all-trans retinoic acid (ATRA) + chemotherapy. During...
6.
Serpa M, Sanabani S, Bendit I, Seguro F, Xavier F, Barroso C, et al.
Clin Med Insights Oncol
. 2011 Jan;
4:155-62.
PMID: 21234296
We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and had switched to dasatinib. The chronic phase...
7.
Bellesso M, Costa S, Pracchia L, Santos Dias L, Chamone D, Dorlhiac-Llacer P
Ann Hematol
. 2010 Sep;
90(4):455-62.
PMID: 20852999
The purpose of this study was to evaluate outcomes such as success of the initial therapy, failure of outpatient treatment, and death in outpatient treatment during intravenous antimicrobial therapy in...
8.
Serpa M, Bendit I, Seguro F, Xavier F, Cavalcante M, Steinbaum D, et al.
Acta Haematol
. 2010 Aug;
124(2):105-9.
PMID: 20720403
While chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) are common diseases in the elderly, they rarely occur simultaneously in the same patient. Here we present the case of...
9.
Conchon M, Sanabani S, Bendit I, Dinardo C, Dias L, Chamone D, et al.
J Transplant
. 2010 Jan;
2009:357093.
PMID: 20107580
We describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who underwent allogeneic bone marrow transplantation (alloBMT) at our institution over a...
10.
Mendrone Jr A, Arrais C, Almeida Neto C, Gualandro S, Dorlhiac-Llacer P, Chamone D, et al.
Transfus Apher Sci
. 2009 Jul;
41(1):13-7.
PMID: 19615943
One limiting factor for automated two-red blood cells collections (2-RBC) is its potential iron depletion. We analyzed hematological parameters and iron balance before, two and four months after 2-RBC of...